Stem definition | Drug id | CAS RN |
---|---|---|
humanized origin | 4924 | 1374853-91-4 |
Molecule | Description |
---|---|
Synonyms:
|
A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.
|
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 28, 2016 | PMDA | MSD K.K. | |
July 17, 2015 | EMA | Merck Sharp & Dohme Limited | |
Sept. 4, 2014 | FDA | MERCK SHARP DOHME |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 1486.09 | 16.78 | 627 | 15741 | 64299 | 46605395 |
Product use in unapproved indication | 574.93 | 16.78 | 370 | 15998 | 89903 | 46579791 |
Immune-mediated adverse reaction | 509.95 | 16.78 | 85 | 16283 | 137 | 46669557 |
Pneumonitis | 237.81 | 16.78 | 139 | 16229 | 28281 | 46641413 |
Immune-mediated hepatitis | 190.64 | 16.78 | 44 | 16324 | 566 | 46669128 |
Hypothyroidism | 178.24 | 16.78 | 120 | 16248 | 31218 | 46638476 |
Hepatitis | 163.50 | 16.78 | 115 | 16253 | 32100 | 46637594 |
Colitis | 152.66 | 16.78 | 117 | 16251 | 37230 | 46632464 |
Hypophysitis | 150.09 | 16.78 | 43 | 16325 | 1350 | 46668344 |
Tubulointerstitial nephritis | 136.10 | 16.78 | 77 | 16291 | 14711 | 46654983 |
Product use issue | 133.37 | 16.78 | 165 | 16203 | 94479 | 46575215 |
Immune-mediated enterocolitis | 132.90 | 16.78 | 30 | 16338 | 347 | 46669347 |
Autoimmune colitis | 132.34 | 16.78 | 31 | 16337 | 427 | 46669267 |
Myocarditis | 131.69 | 16.78 | 61 | 16307 | 7678 | 46662016 |
Tumour pseudoprogression | 126.20 | 16.78 | 25 | 16343 | 144 | 46669550 |
Death | 125.26 | 16.78 | 326 | 16042 | 335222 | 46334472 |
Autoimmune hypothyroidism | 110.06 | 16.78 | 21 | 16347 | 96 | 46669598 |
Fulminant type 1 diabetes mellitus | 105.03 | 16.78 | 23 | 16345 | 229 | 46669465 |
Adverse event | 103.63 | 16.78 | 90 | 16278 | 34094 | 46635600 |
Thyroiditis | 97.07 | 16.78 | 32 | 16336 | 1616 | 46668078 |
Off label use | 96.57 | 16.78 | 322 | 16046 | 379519 | 46290175 |
Type 1 diabetes mellitus | 93.34 | 16.78 | 36 | 16332 | 2874 | 46666820 |
Vitiligo | 92.87 | 16.78 | 28 | 16340 | 1053 | 46668641 |
Immune-mediated hypothyroidism | 85.51 | 16.78 | 13 | 16355 | 6 | 46669688 |
Adrenal insufficiency | 83.66 | 16.78 | 54 | 16314 | 13070 | 46656624 |
Autoimmune hepatitis | 80.95 | 16.78 | 44 | 16324 | 7770 | 46661924 |
Adrenocorticotropic hormone deficiency | 76.00 | 16.78 | 17 | 16351 | 188 | 46669506 |
Hyperthyroidism | 74.19 | 16.78 | 48 | 16320 | 11663 | 46658031 |
Nephritis | 69.30 | 16.78 | 26 | 16342 | 1924 | 46667770 |
Lichenoid keratosis | 67.44 | 16.78 | 23 | 16345 | 1290 | 46668404 |
Autoimmune thyroiditis | 65.37 | 16.78 | 28 | 16340 | 2927 | 46666767 |
Myasthenia gravis | 64.24 | 16.78 | 29 | 16339 | 3437 | 46666257 |
Immune-mediated arthritis | 59.30 | 16.78 | 9 | 16359 | 4 | 46669690 |
Immune-mediated myocarditis | 58.93 | 16.78 | 10 | 16358 | 19 | 46669675 |
Drug hypersensitivity | 58.72 | 16.78 | 8 | 16360 | 243817 | 46425877 |
Immune-mediated pancreatitis | 58.06 | 16.78 | 11 | 16357 | 48 | 46669646 |
Myositis | 56.57 | 16.78 | 35 | 16333 | 7869 | 46661825 |
Cholestasis | 55.06 | 16.78 | 57 | 16311 | 26836 | 46642858 |
Metastatic malignant melanoma | 51.72 | 16.78 | 19 | 16349 | 1325 | 46668369 |
Inappropriate schedule of product administration | 51.11 | 16.78 | 86 | 16282 | 64927 | 46604767 |
Therapy partial responder | 50.27 | 16.78 | 27 | 16341 | 4655 | 46665039 |
Autoimmune arthritis | 49.90 | 16.78 | 9 | 16359 | 28 | 46669666 |
Secondary adrenocortical insufficiency | 47.58 | 16.78 | 16 | 16352 | 859 | 46668835 |
Hepatocellular injury | 47.28 | 16.78 | 55 | 16313 | 29467 | 46640227 |
Drug ineffective | 46.61 | 16.78 | 106 | 16262 | 677732 | 45991962 |
Immune-mediated hepatic disorder | 46.54 | 16.78 | 8 | 16360 | 17 | 46669677 |
Drug effective for unapproved indication | 45.65 | 16.78 | 18 | 16350 | 1524 | 46668170 |
Polymyalgia rheumatica | 44.69 | 16.78 | 20 | 16348 | 2322 | 46667372 |
Immune-mediated thyroiditis | 43.36 | 16.78 | 7 | 16361 | 8 | 46669686 |
Hypopituitarism | 42.01 | 16.78 | 14 | 16354 | 731 | 46668963 |
Uveitis | 41.84 | 16.78 | 30 | 16338 | 8611 | 46661083 |
Immune-mediated dermatitis | 41.74 | 16.78 | 6 | 16362 | 0 | 46669694 |
Diabetic ketoacidosis | 41.67 | 16.78 | 41 | 16327 | 18169 | 46651525 |
Immune-mediated nephritis | 41.17 | 16.78 | 8 | 16360 | 41 | 46669653 |
Autoimmune nephritis | 39.35 | 16.78 | 11 | 16357 | 315 | 46669379 |
Immune-mediated hyperthyroidism | 39.31 | 16.78 | 6 | 16362 | 3 | 46669691 |
Autoimmune pancreatitis | 38.91 | 16.78 | 10 | 16358 | 206 | 46669488 |
Rheumatoid arthritis | 37.06 | 16.78 | 19 | 16349 | 240196 | 46429498 |
Pyrexia | 36.67 | 16.78 | 228 | 16140 | 348574 | 46321120 |
Lichen planus | 36.09 | 16.78 | 16 | 16352 | 1817 | 46667877 |
Lymphocytic hypophysitis | 35.37 | 16.78 | 9 | 16359 | 178 | 46669516 |
Fall | 35.36 | 16.78 | 38 | 16330 | 329059 | 46340635 |
Metastases to central nervous system | 34.90 | 16.78 | 30 | 16338 | 11191 | 46658503 |
Eosinophilic fasciitis | 34.79 | 16.78 | 8 | 16360 | 101 | 46669593 |
Hepatic function abnormal | 34.62 | 16.78 | 51 | 16317 | 34370 | 46635324 |
Dizziness | 33.67 | 16.78 | 42 | 16326 | 340372 | 46329322 |
Drug interaction | 32.94 | 16.78 | 15 | 16353 | 203079 | 46466615 |
Pemphigoid | 32.81 | 16.78 | 22 | 16346 | 5669 | 46664025 |
Neurofibrosarcoma | 32.15 | 16.78 | 8 | 16360 | 144 | 46669550 |
Tumour associated fever | 31.45 | 16.78 | 8 | 16360 | 158 | 46669536 |
Amputation stump pain | 30.83 | 16.78 | 6 | 16362 | 31 | 46669663 |
Subacute cutaneous lupus erythematosus | 29.20 | 16.78 | 14 | 16354 | 1901 | 46667793 |
Polyglandular autoimmune syndrome type II | 29.03 | 16.78 | 6 | 16362 | 44 | 46669650 |
Nasopharyngitis | 28.93 | 16.78 | 9 | 16359 | 153989 | 46515705 |
Hepatitis toxic | 28.61 | 16.78 | 16 | 16352 | 2984 | 46666710 |
Autoimmune myocarditis | 28.15 | 16.78 | 6 | 16362 | 52 | 46669642 |
Autoimmune endocrine disorder | 27.83 | 16.78 | 4 | 16364 | 0 | 46669694 |
Immune-mediated endocrinopathy | 27.83 | 16.78 | 4 | 16364 | 0 | 46669694 |
Transaminases increased | 27.72 | 16.78 | 41 | 16327 | 27720 | 46641974 |
Blood thyroid stimulating hormone increased | 27.55 | 16.78 | 20 | 16348 | 5849 | 46663845 |
Exposure during pregnancy | 27.36 | 16.78 | 3 | 16365 | 108209 | 46561485 |
Joint swelling | 27.34 | 16.78 | 12 | 16356 | 166061 | 46503633 |
Interstitial lung disease | 27.08 | 16.78 | 59 | 16309 | 53890 | 46615804 |
Oligodipsia | 26.00 | 16.78 | 5 | 16363 | 24 | 46669670 |
Immune-mediated neuropathy | 25.59 | 16.78 | 4 | 16364 | 3 | 46669691 |
Radiation pneumonitis | 24.83 | 16.78 | 11 | 16357 | 1246 | 46668448 |
Aspartate aminotransferase increased | 24.71 | 16.78 | 72 | 16296 | 78628 | 46591066 |
Silent thyroiditis | 24.52 | 16.78 | 5 | 16363 | 34 | 46669660 |
Sinusitis | 23.63 | 16.78 | 8 | 16360 | 129760 | 46539934 |
Alanine aminotransferase increased | 23.20 | 16.78 | 76 | 16292 | 88375 | 46581319 |
Skin toxicity | 23.19 | 16.78 | 15 | 16353 | 3639 | 46666055 |
Autoimmune dermatitis | 23.09 | 16.78 | 5 | 16363 | 47 | 46669647 |
Pericardial effusion | 23.06 | 16.78 | 36 | 16332 | 25507 | 46644187 |
Pulmonary embolism | 23.05 | 16.78 | 87 | 16281 | 108498 | 46561196 |
Antinuclear antibody | 22.60 | 16.78 | 8 | 16360 | 501 | 46669193 |
Headache | 22.51 | 16.78 | 89 | 16279 | 478263 | 46191431 |
Toxic epidermal necrolysis | 22.38 | 16.78 | 33 | 16335 | 22245 | 46647449 |
Drug intolerance | 22.11 | 16.78 | 12 | 16356 | 147037 | 46522657 |
Toxicity to various agents | 22.11 | 16.78 | 25 | 16343 | 211741 | 46457953 |
Meningitis aseptic | 21.76 | 16.78 | 15 | 16353 | 4044 | 46665650 |
Pulmonary sarcoidosis | 21.69 | 16.78 | 9 | 16359 | 869 | 46668825 |
Autoimmune uveitis | 21.60 | 16.78 | 4 | 16364 | 15 | 46669679 |
Vesical fistula | 21.14 | 16.78 | 5 | 16363 | 72 | 46669622 |
Overdose | 20.95 | 16.78 | 5 | 16363 | 101974 | 46567720 |
Hepatotoxicity | 20.87 | 16.78 | 34 | 16334 | 24975 | 46644719 |
Sarcoidosis | 20.69 | 16.78 | 16 | 16352 | 5143 | 46664551 |
Melanoma recurrent | 20.59 | 16.78 | 5 | 16363 | 81 | 46669613 |
Neoplasm progression | 20.56 | 16.78 | 35 | 16333 | 26648 | 46643046 |
Cholangitis sclerosing | 20.43 | 16.78 | 9 | 16359 | 1006 | 46668688 |
Cytokine release syndrome | 20.09 | 16.78 | 17 | 16351 | 6206 | 46663488 |
Asthma | 19.79 | 16.78 | 4 | 16364 | 91538 | 46578156 |
Rash maculo-papular | 19.44 | 16.78 | 35 | 16333 | 27839 | 46641855 |
Nephropathy toxic | 19.36 | 16.78 | 18 | 16350 | 7436 | 46662258 |
Thyroid hormones increased | 19.19 | 16.78 | 6 | 16362 | 255 | 46669439 |
Loss of consciousness | 19.15 | 16.78 | 7 | 16361 | 108231 | 46561463 |
Abdominal discomfort | 19.11 | 16.78 | 15 | 16353 | 151150 | 46518544 |
Renal tubular necrosis | 18.84 | 16.78 | 21 | 16347 | 10738 | 46658956 |
Urogenital fistula | 18.57 | 16.78 | 5 | 16363 | 124 | 46669570 |
Bronchitis | 18.50 | 16.78 | 7 | 16361 | 105972 | 46563722 |
Cholecystitis | 18.39 | 16.78 | 24 | 16344 | 14442 | 46655252 |
Serous retinal detachment | 18.39 | 16.78 | 5 | 16363 | 129 | 46669565 |
Adenocarcinoma | 18.30 | 16.78 | 11 | 16357 | 2348 | 46667346 |
Blood pressure abnormal | 18.29 | 16.78 | 22 | 16346 | 12195 | 46657499 |
Immune-mediated myositis | 18.05 | 16.78 | 8 | 16360 | 908 | 46668786 |
Pleural effusion | 18.04 | 16.78 | 67 | 16301 | 82885 | 46586809 |
Vital functions abnormal | 17.97 | 16.78 | 6 | 16362 | 315 | 46669379 |
No adverse event | 17.82 | 16.78 | 38 | 16330 | 34193 | 46635501 |
Condition aggravated | 17.82 | 16.78 | 37 | 16331 | 245015 | 46424679 |
Cholangitis | 17.68 | 16.78 | 14 | 16354 | 4660 | 46665034 |
SJS-TEN overlap | 17.60 | 16.78 | 5 | 16363 | 152 | 46669542 |
Achromotrichia acquired | 17.58 | 16.78 | 3 | 16365 | 6 | 46669688 |
Radiation associated pain | 17.51 | 16.78 | 4 | 16364 | 49 | 46669645 |
Pneumonia moraxella | 17.51 | 16.78 | 4 | 16364 | 49 | 46669645 |
Cheilitis | 17.39 | 16.78 | 13 | 16355 | 3975 | 46665719 |
Autoimmune thyroid disorder | 17.26 | 16.78 | 3 | 16365 | 7 | 46669687 |
Roseolovirus test positive | 17.15 | 16.78 | 4 | 16364 | 54 | 46669640 |
Myasthenia gravis crisis | 17.00 | 16.78 | 6 | 16362 | 373 | 46669321 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 1921.10 | 15.40 | 984 | 21981 | 71303 | 29858210 |
Immune-mediated adverse reaction | 912.45 | 15.40 | 176 | 22789 | 300 | 29929213 |
Product use in unapproved indication | 475.86 | 15.40 | 417 | 22548 | 73276 | 29856237 |
Pneumonitis | 390.84 | 15.40 | 250 | 22715 | 27204 | 29902309 |
Interstitial lung disease | 309.11 | 15.40 | 300 | 22665 | 59897 | 29869616 |
Adverse event | 213.92 | 15.40 | 138 | 22827 | 15203 | 29914310 |
Myasthenia gravis | 213.70 | 15.40 | 82 | 22883 | 2910 | 29926603 |
Adrenal insufficiency | 202.16 | 15.40 | 116 | 22849 | 10347 | 29919166 |
Hypothyroidism | 190.10 | 15.40 | 127 | 22838 | 14836 | 29914677 |
Immune-mediated hepatitis | 187.47 | 15.40 | 58 | 22907 | 1058 | 29928455 |
Product use issue | 181.13 | 15.40 | 199 | 22766 | 45817 | 29883696 |
Immune-mediated enterocolitis | 177.53 | 15.40 | 55 | 22910 | 1008 | 29928505 |
Colitis | 164.33 | 15.40 | 157 | 22808 | 30663 | 29898850 |
Type 1 diabetes mellitus | 157.36 | 15.40 | 70 | 22895 | 3629 | 29925884 |
Off label use | 156.83 | 15.40 | 482 | 22483 | 248808 | 29680705 |
Myocarditis | 154.37 | 15.40 | 96 | 22869 | 9915 | 29919598 |
Tumour pseudoprogression | 151.17 | 15.40 | 38 | 22927 | 306 | 29929207 |
Hypophysitis | 150.80 | 15.40 | 56 | 22909 | 1812 | 29927701 |
Immune-mediated myocarditis | 147.59 | 15.40 | 29 | 22936 | 57 | 29929456 |
Autoimmune hepatitis | 139.57 | 15.40 | 64 | 22901 | 3563 | 29925950 |
Autoimmune colitis | 127.22 | 15.40 | 40 | 22925 | 771 | 29928742 |
Vitiligo | 120.20 | 15.40 | 37 | 22928 | 663 | 29928850 |
Immune-mediated hypothyroidism | 114.53 | 15.40 | 19 | 22946 | 3 | 29929510 |
Myositis | 110.41 | 15.40 | 79 | 22886 | 10298 | 29919215 |
Immune-mediated hepatic disorder | 108.73 | 15.40 | 21 | 22944 | 36 | 29929477 |
Therapy partial responder | 102.25 | 15.40 | 52 | 22913 | 3639 | 29925874 |
Tubulointerstitial nephritis | 100.77 | 15.40 | 94 | 22871 | 17797 | 29911716 |
Pemphigoid | 98.24 | 15.40 | 65 | 22900 | 7463 | 29922050 |
Hyperthyroidism | 89.26 | 15.40 | 63 | 22902 | 8035 | 29921478 |
Immune-mediated arthritis | 85.40 | 15.40 | 16 | 22949 | 21 | 29929492 |
Thyroiditis | 79.61 | 15.40 | 34 | 22931 | 1595 | 29927918 |
Drug interaction | 79.52 | 15.40 | 27 | 22938 | 199541 | 29729972 |
Immune-mediated myositis | 73.49 | 15.40 | 30 | 22935 | 1255 | 29928258 |
Adrenocorticotropic hormone deficiency | 70.36 | 15.40 | 22 | 22943 | 416 | 29929097 |
Inappropriate schedule of product administration | 68.40 | 15.40 | 115 | 22850 | 39613 | 29889900 |
Death | 68.15 | 15.40 | 487 | 22478 | 356796 | 29572717 |
Hepatitis | 66.75 | 15.40 | 84 | 22881 | 22272 | 29907241 |
Nephritis | 65.15 | 15.40 | 32 | 22933 | 2078 | 29927435 |
Completed suicide | 63.69 | 15.40 | 3 | 22962 | 99489 | 29830024 |
Polymyalgia rheumatica | 60.74 | 15.40 | 25 | 22940 | 1068 | 29928445 |
Fall | 53.58 | 15.40 | 37 | 22928 | 181835 | 29747678 |
Organising pneumonia | 52.52 | 15.40 | 38 | 22927 | 5036 | 29924477 |
Autoimmune hypothyroidism | 52.45 | 15.40 | 11 | 22954 | 34 | 29929479 |
Autoimmune thyroiditis | 52.20 | 15.40 | 22 | 22943 | 998 | 29928515 |
Hypopituitarism | 51.57 | 15.40 | 25 | 22940 | 1577 | 29927936 |
Autoimmune arthritis | 51.29 | 15.40 | 11 | 22954 | 39 | 29929474 |
Overdose | 46.94 | 15.40 | 5 | 22960 | 84332 | 29845181 |
Immune-mediated uveitis | 46.85 | 15.40 | 8 | 22957 | 3 | 29929510 |
Hepatic function abnormal | 46.85 | 15.40 | 101 | 22864 | 41844 | 29887669 |
Secondary adrenocortical insufficiency | 45.68 | 15.40 | 20 | 22945 | 997 | 29928516 |
Autoimmune myocarditis | 45.59 | 15.40 | 12 | 22953 | 118 | 29929395 |
Metastatic malignant melanoma | 45.52 | 15.40 | 25 | 22940 | 2045 | 29927468 |
Diabetic ketoacidosis | 44.46 | 15.40 | 58 | 22907 | 15928 | 29913585 |
Eyelid ptosis | 42.95 | 15.40 | 34 | 22931 | 5154 | 29924359 |
Fulminant type 1 diabetes mellitus | 42.63 | 15.40 | 16 | 22949 | 533 | 29928980 |
Cholangitis sclerosing | 41.02 | 15.40 | 18 | 22947 | 902 | 29928611 |
Immune-mediated thyroiditis | 40.73 | 15.40 | 7 | 22958 | 3 | 29929510 |
Lichenoid keratosis | 39.84 | 15.40 | 23 | 22942 | 2071 | 29927442 |
Immune-mediated pancreatitis | 39.39 | 15.40 | 8 | 22957 | 20 | 29929493 |
Lymphocytic hypophysitis | 38.52 | 15.40 | 11 | 22954 | 150 | 29929363 |
Autoimmune nephritis | 37.36 | 15.40 | 11 | 22954 | 168 | 29929345 |
Rash | 37.19 | 15.40 | 263 | 22702 | 191626 | 29737887 |
Hepatocellular injury | 36.42 | 15.40 | 68 | 22897 | 25403 | 29904110 |
Haemophagocytic lymphohistiocytosis | 36.14 | 15.40 | 41 | 22924 | 9750 | 29919763 |
Lung disorder | 35.39 | 15.40 | 76 | 22889 | 31393 | 29898120 |
Diarrhoea | 35.33 | 15.40 | 401 | 22564 | 333702 | 29595811 |
Drug effective for unapproved indication | 34.92 | 15.40 | 17 | 22948 | 1082 | 29928431 |
Encephalitis autoimmune | 34.64 | 15.40 | 13 | 22952 | 433 | 29929080 |
Pneumonia bacterial | 34.07 | 15.40 | 39 | 22926 | 9364 | 29920149 |
Immune thrombocytopenia | 33.63 | 15.40 | 35 | 22930 | 7556 | 29921957 |
Encephalitis | 32.77 | 15.40 | 32 | 22933 | 6404 | 29923109 |
Autoimmune pancreatitis | 32.52 | 15.40 | 11 | 22954 | 269 | 29929244 |
Immune-mediated dermatitis | 31.97 | 15.40 | 6 | 22959 | 8 | 29929505 |
Toxicity to various agents | 31.26 | 15.40 | 55 | 22910 | 177128 | 29752385 |
Immune-mediated endocrinopathy | 30.87 | 15.40 | 5 | 22960 | 0 | 29929513 |
Tumour hyperprogression | 30.81 | 15.40 | 6 | 22959 | 11 | 29929502 |
Paraneoplastic neurological syndrome | 30.81 | 15.40 | 6 | 22959 | 11 | 29929502 |
Dizziness | 30.48 | 15.40 | 65 | 22900 | 194844 | 29734669 |
Immune-mediated nephritis | 29.58 | 15.40 | 8 | 22957 | 88 | 29929425 |
Immune-mediated renal disorder | 28.52 | 15.40 | 5 | 22960 | 3 | 29929510 |
Autoimmune uveitis | 28.52 | 15.40 | 5 | 22960 | 3 | 29929510 |
Skin toxicity | 28.42 | 15.40 | 22 | 22943 | 3227 | 29926286 |
Melanoma recurrent | 28.36 | 15.40 | 8 | 22957 | 104 | 29929409 |
Neoplasm progression | 28.15 | 15.40 | 50 | 22915 | 17973 | 29911540 |
Silent thyroiditis | 27.82 | 15.40 | 6 | 22959 | 22 | 29929491 |
Metastases to central nervous system | 27.73 | 15.40 | 31 | 22934 | 7253 | 29922260 |
Immune-mediated encephalitis | 27.61 | 15.40 | 6 | 22959 | 23 | 29929490 |
Thyroid disorder | 27.35 | 15.40 | 20 | 22945 | 2694 | 29926819 |
Cancer pain | 26.49 | 15.40 | 19 | 22946 | 2483 | 29927030 |
Plasma cell myeloma | 25.50 | 15.40 | 5 | 22960 | 53457 | 29876056 |
Haemoglobin decreased | 25.45 | 15.40 | 30 | 22935 | 114068 | 29815445 |
Drug ineffective | 24.95 | 15.40 | 156 | 22809 | 340231 | 29589282 |
Enteritis | 24.82 | 15.40 | 28 | 22937 | 6617 | 29922896 |
Drug hypersensitivity | 24.37 | 15.40 | 11 | 22954 | 68508 | 29861005 |
Eosinophilic fasciitis | 24.08 | 15.40 | 7 | 22958 | 102 | 29929411 |
Hypotension | 23.65 | 15.40 | 77 | 22888 | 200488 | 29729025 |
Headache | 23.62 | 15.40 | 67 | 22898 | 182239 | 29747274 |
Hypothalamo-pituitary disorder | 23.60 | 15.40 | 11 | 22954 | 635 | 29928878 |
Cutaneous sarcoidosis | 23.53 | 15.40 | 7 | 22958 | 111 | 29929402 |
Rheumatoid nodule | 23.03 | 15.40 | 15 | 22950 | 1675 | 29927838 |
Anxiety | 23.00 | 15.40 | 21 | 22944 | 89850 | 29839663 |
Insomnia | 22.51 | 15.40 | 23 | 22942 | 93313 | 29836200 |
Depression | 22.13 | 15.40 | 22 | 22943 | 90415 | 29839098 |
Decreased appetite | 22.10 | 15.40 | 193 | 22772 | 149717 | 29779796 |
Pulmonary sarcoidosis | 21.48 | 15.40 | 10 | 22955 | 576 | 29928937 |
Hospitalisation | 21.44 | 15.40 | 4 | 22961 | 44315 | 29885198 |
Cardiac arrest | 21.14 | 15.40 | 24 | 22941 | 92826 | 29836687 |
Dermatomyositis | 21.12 | 15.40 | 12 | 22953 | 1048 | 29928465 |
Colitis microscopic | 20.52 | 15.40 | 14 | 22951 | 1689 | 29927824 |
Lichen planus | 20.39 | 15.40 | 11 | 22954 | 868 | 29928645 |
Agitation | 20.32 | 15.40 | 8 | 22957 | 54065 | 29875448 |
Pericarditis malignant | 20.31 | 15.40 | 4 | 22961 | 8 | 29929505 |
Primary hypothyroidism | 20.03 | 15.40 | 5 | 22960 | 39 | 29929474 |
Mucosal inflammation | 19.96 | 15.40 | 60 | 22905 | 30434 | 29899079 |
Latent autoimmune diabetes in adults | 19.70 | 15.40 | 5 | 22960 | 42 | 29929471 |
Cholangitis | 19.68 | 15.40 | 27 | 22938 | 7775 | 29921738 |
Autoimmune neuropathy | 19.49 | 15.40 | 5 | 22960 | 44 | 29929469 |
Respiratory failure | 19.47 | 15.40 | 138 | 22827 | 100504 | 29829009 |
Lymph node abscess | 19.16 | 15.40 | 4 | 22961 | 12 | 29929501 |
Adrenalitis | 19.16 | 15.40 | 4 | 22961 | 12 | 29929501 |
Pancreatic failure | 19.09 | 15.40 | 10 | 22955 | 744 | 29928769 |
Transitional cell carcinoma recurrent | 18.69 | 15.40 | 4 | 22961 | 14 | 29929499 |
Tumour ulceration | 18.66 | 15.40 | 5 | 22960 | 53 | 29929460 |
Pyrexia | 18.65 | 15.40 | 323 | 22642 | 294166 | 29635347 |
Autoimmune cholangitis | 18.52 | 15.40 | 3 | 22962 | 0 | 29929513 |
Non-small cell lung cancer stage III | 18.52 | 15.40 | 3 | 22962 | 0 | 29929513 |
Optic neuritis | 18.21 | 15.40 | 17 | 22948 | 3217 | 29926296 |
Cardiac tamponade | 18.08 | 15.40 | 20 | 22945 | 4624 | 29924889 |
International normalised ratio increased | 18.04 | 15.40 | 7 | 22958 | 47732 | 29881781 |
Drug-induced liver injury | 18.02 | 15.40 | 46 | 22919 | 21228 | 29908285 |
Fatigue | 17.96 | 15.40 | 345 | 22620 | 320328 | 29609185 |
Limbic encephalitis | 17.75 | 15.40 | 7 | 22958 | 267 | 29929246 |
Pleural effusion | 17.63 | 15.40 | 107 | 22858 | 73959 | 29855554 |
Blood corticotrophin decreased | 17.50 | 15.40 | 6 | 22959 | 153 | 29929360 |
Hallucination | 17.25 | 15.40 | 8 | 22957 | 49051 | 29880462 |
Hepatotoxicity | 17.24 | 15.40 | 41 | 22924 | 18104 | 29911409 |
Hypersensitivity | 17.23 | 15.40 | 10 | 22955 | 54018 | 29875495 |
Syncope | 17.19 | 15.40 | 24 | 22941 | 84879 | 29844634 |
Bradycardia | 17.14 | 15.40 | 15 | 22950 | 65511 | 29864002 |
Hepatitis E virus test positive | 17.08 | 15.40 | 4 | 22961 | 23 | 29929490 |
Autoimmune disorder | 17.02 | 15.40 | 12 | 22953 | 1527 | 29927986 |
Cachexia | 16.86 | 15.40 | 23 | 22942 | 6588 | 29922925 |
Toxic epidermal necrolysis | 16.47 | 15.40 | 40 | 22925 | 17900 | 29911613 |
Radiation pneumonitis | 16.35 | 15.40 | 13 | 22952 | 1983 | 29927530 |
Pain in extremity | 16.18 | 15.40 | 38 | 22927 | 110183 | 29819330 |
Non-small cell lung cancer | 16.17 | 15.40 | 17 | 22948 | 3713 | 29925800 |
Transaminases increased | 16.15 | 15.40 | 47 | 22918 | 23410 | 29906103 |
Pruritus | 15.78 | 15.40 | 149 | 22816 | 118055 | 29811458 |
Metastases to skin | 15.55 | 15.40 | 7 | 22958 | 373 | 29929140 |
Melaena | 15.54 | 15.40 | 3 | 22962 | 32434 | 29897079 |
Liver disorder | 15.40 | 15.40 | 54 | 22911 | 29668 | 29899845 |
Source | Code | Description |
---|---|---|
ATC | L01XC18 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Monoclonal antibodies |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D000074322 | Antineoplastic Agents, Immunological |
FDA MoA | N0000191259 | Programmed Death Receptor-1-directed Antibody Interactions |
FDA EPC | N0000191260 | Programmed Death Receptor-1 Blocking Antibody |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Non-small cell lung cancer | indication | 254637007 | DOID:3908 |
Malignant tumor of head and/or neck | indication | 255056009 | |
Metastatic malignant melanoma | indication | 443493003 | |
Metastatic renal cell carcinoma | indication | 702392008 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Programmed cell death protein 1 | Membrane receptor | ANTIBODY BINDING | Kd | 10 | IUPHAR | DRUG LABEL |
ID | Source |
---|---|
D10574 | KEGG_DRUG |
4033703 | VUID |
N0000191088 | NUI |
4033703 | VANDF |
C3855203 | UMLSCUI |
CHEMBL3137343 | ChEMBL_ID |
DB09037 | DRUGBANK_ID |
C582435 | MESH_SUPPLEMENTAL_RECORD_UI |
7499 | IUPHAR_LIGAND_ID |
9798 | INN_ID |
DPT0O3T46P | UNII |
1547545 | RXNORM |
228586 | MMSL |
30533 | MMSL |
d08287 | MMSL |
015666 | NDDF |
716125002 | SNOMEDCT_US |
763541003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
KEYTRUDA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3026 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | BLA | 28 sections |
KEYTRUDA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3026 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | BLA | 28 sections |
KEYTRUDA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3029 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | BLA | 28 sections |
KEYTRUDA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3029 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | BLA | 28 sections |